Previous studies have demonstrated the efficacy of targeting the Wnt/β-catenin pathway in various cancers (34), suggesting that pharmacological modulation of BAIAP2L2-associated signaling might enhance the efficacy of existing PCa therapies. This evidence concerns the gene BAIAP2L2 and cancer.